Clinical Trials

NCT Number: NCT06039371 Phase: PHASE2 Trial Summary: This phase II trial studies how well giving testosterone at levels higher than normally found in the body (supraphysiological) works to enhance chemotherapy treatment in patients with prostate cancer – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Washington Acronym:

NCT Number: NCT06084338 Phase: PHASE2 Trial Summary: This trial tests if the combination of comprehensive metastasis directed therapy delivered by a precision form of external beam radiotherapy (stereotactic ablative radiotherapy), combined with PSMA ta – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): VA Office of Research and Development Acronym:

NCT Number: NCT06100705 Phase: PHASE2 Trial Summary: This is an open-label, single-arm phase II study of bipolar androgen therapy (BAT) given in addition with standard of care Sipuleucel-T to determine the interferon (IFN) gamma Enzyme-linked Immunospot – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Yale University Acronym:

NCT Number: NCT06112990 Phase: PHASE3 Trial Summary: The goal of this clinical trial is to test the use of creatine monohydrate supplementation with resistance training to preserve muscle mass and help lessen prostate cancer progression. The main quest – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Utah Acronym: CREATINE-52

NCT Number: NCT06136624 Phase: PHASE3 Trial Summary: This is a phase 3, randomized, open-label study of MK-5684 compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Merck Sharp & Dohme LLC Acronym:

NCT Number: NCT06136650 Phase: PHASE3 Trial Summary: The purpose of this study is to assess the efficacy and safety of MK-5684 plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metast – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Merck Sharp & Dohme LLC Acronym:

NCT Number: NCT05806814 Phase: PHASE1 Trial Summary: Proposed immunotherapy with an extended course of Sipuleucel-T treatment may induce a more robust immune response and improve the anti-cancer efficacy of Sipuleucel-T in patients with metastatic Castr – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Oklahoma Acronym: OUSCCEXCITE

NCT Number: NCT04586270 Phase: PHASE1 Trial Summary: The purpose of this study is to see if TAS0612 is safe in participants with advanced or metastatic solid tumor cancer. – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Taiho Oncology, Inc. Acronym:

NCT Number: NCT05806515 Phase: PHASE2 Trial Summary: This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medi – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): SWOG Cancer Research Network Acronym:

NCT Number: NCT05946213 Phase: PHASE3 Trial Summary: This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): NRG Oncology Acronym: